

LifeCell unveils drug resistance TB test in partnership with HaystackAnalytics

07 December 2022 | News

Collaboration to bring the groundbreaking TB testing solution further closer to the patients



LifeCell has announced the launch of a revolutionary genetic test – Omega TB, in partnership with HaystackAnalytics, a genomics based health-tech startup. The collaboration marks LifeCell's foray into the genetic testing industry for TB patients.

The whole genome sequencing (WGS) test, designed by Haystack Analytics, aims to tackle the looming challenge of drug resistance. Apart from this, the test also helps in treating and preventing the spread of tuberculosis (TB) by providing timely, affordable and accurate diagnosis.

The current culture and molecular tests providing limited information can take up to weeks for results. Omega TB is a single test that identifies all diagnostic information on TB infections. The test screens resistance of 18 listed antibiotics and shares results in just 10-12 days.

LifeCell's whole genome sequencing (WGS) in collaboration with HaystackAnalytics can identify low-frequency resistance mutations and heterogeneous resistance with greater sensitivity. Moreover, WGS is also well-known in predicting resistant phenotypes against anti-TB drugs, designing optimum personalised treatment regimen, thereby enhancing favorable treatment outcomes in TB endemic settings.

With the launch of this affordable genome sequence analysis test, clinicians and patients will have access to one of the most powerful assessment tools to get vital insights and directions. This will help in early prevention and screening of a critical disease like TB. Affordable rates are available for these tests.